Lycotec Patented First Nutra-Pharmaceutical Drug to Treat Infection Behind Cardiovascular Disease – Benzinga


Lycotec Ltd. has filed a patent application for the first drug in the treatment of a bacterial infection which could be involved in the development of atherosclerosis and cardiovascular disease, CVD.

Cambridge UK (PRWEB UK) 30 January 2017

Lycotec Ltd., a biotech company based in Cambridge UK, http://www.lycotec.com has filed a patent application for the first drug in the treatment of a bacterial infection which could be involved in the development of atherosclerosis and cardiovascular disease, CVD.

An infection as a cause of cardiovascular pathology has been sought for more than 100 years. In the last 20-25 years a number of bacteria and viruses have been identified in atherosclerotic plaques of people with CVD. One of the most reported findings was a detection of fragments, DNA…



Full article from the Source…

Back to Top